Inhibiting PRC2 has been associated with a risk of developing blood cancer, an issue US regulators flagged when stopping testing of FTX6058 in February. The FDA asked Fulcrum to narrow testing to a group where the potential benefits outweighed the risks leading to the study design the company will carry forward